Investment Opportunities in Singapore’s Biopharma Sector

Singapore has rapidly established itself as a leading biopharmaceutical hub in Asia, attracting global giants and pioneering startups with its innovation-focused ecosystem. In 2024 alone, Singapore secured S$13.5 billion in fixed asset investment commitments, with the biomedical sector representing a significant share of the S$11.1 billion directed toward industrial development. Biopharma activities now generate over S$20 billion annually in output, highlighting the sector’s critical role in Singapore’s economy.

With global demand for targeted therapies and high-end manufacturing surging, Singapore’s biopharma industry is entering a transformative growth phase that offers timely opportunities for strategic investors.

Why Singapore stands out for biopharma investment

Singapore’s competitive edge in biopharma stems from a convergence of policy support, infrastructure, and talent. The Economic Development Board (EDB) continues to implement sector-wide initiatives under the Research, Innovation and Enterprise (RIE) 2025 strategy, focusing on next-generation technologies like AI-enabled drug discovery and precision medicine. Regulatory clarity provided by the Health Sciences Authority, a strong IP protection framework, and Singapore’s reputation as a safe, rule-of-law jurisdiction contribute to investor confidence.

On the infrastructure front, hubs like Biopolis and Tuas Biomedical Park offer plug-and-play facilities that reduce entry barriers. In 2024, WuXi Biologics broke ground on a US$1.4 billion CRDMO facility in Tuas, while AstraZeneca announced plans for a US$1.5 billion site to produce antibody-drug conjugates (ADCs), solidifying Singapore’s position as a global center for high-value biomanufacturing.

High-growth areas within the sector

The range of investible segments in Singapore’s biopharma sector continues to expand. Advanced manufacturing remains a cornerstone, with multinational firms scaling production of complex biologics. AstraZeneca’s commitment to producing ADCs, an emerging class of targeted cancer therapies, highlights the country’s alignment with cutting-edge therapeutic trends.

Research and development, particularly in genomics and personalized medicine, are backed by significant public funding and active collaboration between academia and industry. Singapore has committed over S$1 billion to biomedical R&D under the RIE2025 plan, including a dedicated S$80 million initiative for cell and gene therapy manufacturing.

Meanwhile, contract research organizations (CROs) are proliferating as companies outsource regulatory and clinical trial processes. Singapore’s growing footprint in digital health, AI-based molecule discovery, and gene therapies offers new frontiers for investors seeking exposure to innovation-driven subsectors.

Who’s driving the sector forward?

The biopharma ecosystem in Singapore is anchored by established multinationals and supported by a pipeline of promising local ventures. Companies such as GSK, Pfizer, and Roche have long maintained substantial operations in Singapore. In 2024, AstraZeneca’s investment further reinforced the country’s appeal as a manufacturing base for biologics and novel therapeutics.

On the local front, companies like MiRXES continue to grow in areas such as RNA diagnostics and early cancer detection, supported by a thriving innovation ecosystem. Institutions like ASTAR and its commercialization arm, Accelerate, play a crucial role in connecting early-stage research to real-world applications. The number of biotech companies has surged from about a dozen in 2015 to over 60 in 2025, reflecting a vibrant startup scene.

Meanwhile, Singapore’s biopharma workforce has grown to over 25,000 employees, a more than 40 percent increase since 2015, driven by both foreign investment and government-backed training programs.

Pathways for investment and expansion

Investors can tap into Singapore’s biopharma sector through multiple routes. Direct equity investments into leading startups or scaling companies offer targeted exposure, while venture capital and private equity funds focused on health sciences provide diversified access. With the construction of billion-dollar manufacturing plants and the expansion of R&D centers, opportunities for partnerships and joint ventures are multiplying. Institutions such as A*STAR regularly license breakthrough technologies that can be commercialized with the right strategic partner.

Government-backed schemes such as Startup SG and EDB’s co-investment programs also offer capital support and risk-sharing options to incentivize new entrants.

Risks to navigate in a competitive landscape

Despite its many advantages, investors should be aware of sectoral risks. Regulatory approval timelines, though internationally respected, can slow down time-to-market strategies, particularly for novel therapies. Singapore also faces stiff competition from other Asian biopharma hubs such as South Korea and China, where governments aggressively subsidize local ecosystems.

A notable concern in 2025 has been the volatility in biomedical output. Singapore’s biomedical manufacturing output declined by 14.3 percent in February 2025 compared to the previous year, with pharmaceutical production dropping by 30 percent. This fluctuation highlights the need for a long-term view and a diversified investment approach. Additionally, securing specialized talent remains a challenge.

While Singapore boasts a deep talent pool, the demand for specialists in clinical genetics, cancer biology, and microbiology outpaces supply, especially as the sector becomes more technology-intensive.

However, new biopharma investments in 2024 alone are projected to create at least 1,000 new jobs, particularly in advanced manufacturing roles.

Where the sector is headed

Singapore’s biopharma sector remains on a strong trajectory despite occasional volatility. The government is committed to deepening the sector’s capabilities through expanded public-private collaboration, enhanced clinical trial infrastructure, and the development of new biomedical clusters.

As the global life sciences landscape shifts toward personalized medicine and AI-driven drug development, Singapore is positioning itself at the forefront of regional innovation.

• Previous Article Tariffs and Chips: Singapore’s Talks with the U.S.
• Next Article Indonesia Plans to Shift Fuel Sourcing from Singapore